Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

(ATLANTA, December 8, 2012) The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

CLL is a blood cancer that causes abnormal white blood cells called lymphocytes to accumulate in the blood, bone marrow, and in the lymph nodes or other organs, causing these organs to enlarge. Approximately 15,000 Americans are diagnosed with CLL every year; nearly 70 percent of those affected are 65 and older. , For some patients with slower growing disease, physicians employ "watch and wait" strategies to minimize unnecessary treatment. However, patients with high-risk features such as rapidly progressing disease require prompt treatment to manage symptoms and reduce organ damage.

Ibrutinib is a specialized anti-cancer therapy that targets the Bruton's tyrosine kinase (BTK, an enzyme important in the development of CLL). As an inhibitor of BTK, ibrutinib selectively targets leukemia cells, promoting their death and preventing them from growing while leaving normal cells unharmed. Studies suggest this design allows the drug to more effectively treat the disease, with encouraging early results in harder-to-treat patient groups such as elderly untreated patients and those whose disease has become resistant to other therapies or those who have experienced disease recurrence after receiving other therapies. Two studies will present efficacy and safety results testing the compound alone and in combination with other currently used therapies for CLL.

"The evidence collected to date on ibrutinib demonstrates that it may have the potential to improve long-term prognosis for patients who are not sensitive to standard treatment," said Claire E. Dearden, MD, moderator of the press conf
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 An inventor and ... to the problem of side-sleeping. "My lower arm always ... I designed a solution to this problem," she said. ... than to have your arm 'fall asleep.'" , The ... or her side more comfortably. It avoids pain and ...
(Date:9/22/2014)... 2014 Quincy Bioscience, one of ... promotes National Self-Improvement Month this September. ... should have access to self-improvement resources, especially for ... demand for products that preserve health is growing ... For over six years, Quincy Bioscience has been ...
(Date:9/22/2014)... The Workgroup for Electronic Data ... on the use of health IT to create ... its recent industry survey on the use of ... transactions adopted under the Health Insurance Portability and ... August 20 to September 5, which included 262 ...
(Date:9/22/2014)... new prescription devices approved by the U.S. Food and ... with migraine headaches who don,t tolerate migraine medications well, ... the Cefaly -- is designed to prevent migraines, while ... to be used when migraines first start, according to ... for alternative migraine treatments. Because these devices aren,t ingested ...
(Date:9/22/2014)... Pain does not need to rule your ... and reader-friendly book designed to guide the individual who suffers ... inspirational book is written to help the reader who is ... to regain a pain-free life — a daily “go-to” guide ... Chronic pain has become an epidemic, with over 100 million ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2
... surgeons offer tips on knowing when you,re ready to drive again ... the drive to get behind the wheel again after orthopedic surgery ... as simple as turning the key. , Orthopedic surgeons weigh in ... of Bone and Joint Surgery . , "Deciding when a ...
... Son Featured in TV and Radio Ads , ... Advertising Council, in partnership with Autism Speaks, announced today the ... featuring Grammy award-winning recording artist Toni Braxton and her son, ... parents to learn the early warning signs of this developmental ...
... Targeted Therapies to Achieve Better Efficacy and Toxicity Profiles Than ... , , WALTHAM, Mass., Dec. ... and advisory firms focusing on pharmaceutical and healthcare issues, forecasts ... from $35 million in 2007 to $64 million by 2012. ...
... Wisconsin Among States with Hurdles Ahead, According to New ... , NASHVILLE, Tenn., Dec. 10 HealthLeaders-InterStudy, ... that states will face pressure to re-examine their government-sponsored ... lose their jobs or come off severance packages and ...
... , RESEARCH TRIANGLE PARK, ... provider of drug development and manufacturing services to the ... of its new U.S. headquarters and analytical lab facilities ... Carolina. , Established nearly five decades ago ...
... Non-Cash Write-Down for MAPLE Asset and MDS Pharma Services, ... 10 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ ... life-sciences markets, today provided an update for fiscal 2008 performance. , ... fiscal 2008 net revenue in the range of $1,210 million to ...
Cached Medicine News:Health News:Returning to the Road Tricky After Injury 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 4Health News:India's Breast Cancer Drug Market Will Almost Double by 2012 2Health News:Economic Downturn Means Increased Demands on Budget-Challenged State Health Coverage Initiatives 2Health News:Economic Downturn Means Increased Demands on Budget-Challenged State Health Coverage Initiatives 3Health News:Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC 2Health News:Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC 3Health News:MDS Provides Update on Fiscal 2008 Performance 2Health News:MDS Provides Update on Fiscal 2008 Performance 3Health News:MDS Provides Update on Fiscal 2008 Performance 4
(Date:9/22/2014)... MEETING, Pa. , Sept. 22, 2014 /PRNewswire/ ... announced today it has initiated a phase I ... trial will evaluate the safety, tolerability, and immunogenicity ... 6 (HPV-6), which causes most aerodigestive cancers. ... nose, throat, vocal cords, and parts of the ...
(Date:9/22/2014)... and NEW YORK , ... (OTCBB: ACCP), has signed an exclusive, global license ... development and commercialization of its proprietary plasma fractionation ... management team and its intention to strategically refocus ... and its plans to pursue a national listing ...
(Date:9/22/2014)... CHESTERBROOK, Pa. , Sept. 22, 2014 /PRNewswire/ ... ), a specialty biopharmaceutical company, today announced that ... the unsolicited, non-binding and conditional proposal from Endo ... independent financial and legal advisors, has unanimously determined ... terms of its existing merger agreement with QLT ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... OAKBROOK TERRACE, Ill., Sept. 16 Pain is,just ... actually one of the main,reasons that Americans seek medical ... recovery times, poor quality of life and higher,health care ... campaign to help Americans,work with their health care professionals ...
... Expand NHL Marketplace with, Novel Antibody and Speedy ... COLUMBIA, Canada, Sept. 16 InNexus,Biotechnology Inc. (TSX ... a drug development company commercializing the next,generation of ... (DXL(TM)), announced today the results of an extensive ...
Cached Medicine Technology:Joint Commission Urges Patients to 'Speak Up' About Pain 2Joint Commission Urges Patients to 'Speak Up' About Pain 3InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies 2InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies 3
Knife rasp for shoulder arthroscopy....
Loop handle knot pusher...
Shoulder rasp...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Medicine Products: